NO986103D0 - Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE - Google Patents

Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE

Info

Publication number
NO986103D0
NO986103D0 NO986103A NO986103A NO986103D0 NO 986103 D0 NO986103 D0 NO 986103D0 NO 986103 A NO986103 A NO 986103A NO 986103 A NO986103 A NO 986103A NO 986103 D0 NO986103 D0 NO 986103D0
Authority
NO
Norway
Prior art keywords
pde
phosphodiesterase
indazole derivatives
substituted indazole
substituted
Prior art date
Application number
NO986103A
Other languages
English (en)
Norwegian (no)
Other versions
NO986103L (no
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO986103D0 publication Critical patent/NO986103D0/no
Publication of NO986103L publication Critical patent/NO986103L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO986103A 1996-06-25 1998-12-23 Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE)type IV - og tumornekrose-faktor (TNF)inhibitorer NO986103L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25
PCT/IB1997/000630 WO1997049702A1 (en) 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors

Publications (2)

Publication Number Publication Date
NO986103D0 true NO986103D0 (no) 1998-12-23
NO986103L NO986103L (no) 1998-12-23

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
NO986103A NO986103L (no) 1996-06-25 1998-12-23 Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE)type IV - og tumornekrose-faktor (TNF)inhibitorer

Country Status (42)

Country Link
US (1) US6040329A (is)
EP (1) EP0912558B1 (is)
JP (1) JP3152940B2 (is)
KR (1) KR20000022516A (is)
CN (1) CN1080260C (is)
AP (1) AP1025A (is)
AR (1) AR007456A1 (is)
AT (1) ATE244713T1 (is)
AU (1) AU716376B2 (is)
BG (1) BG64052B1 (is)
BR (1) BR9712782A (is)
CA (1) CA2258285C (is)
CO (1) CO4900056A1 (is)
CZ (1) CZ423398A3 (is)
DE (1) DE69723447T2 (is)
DK (1) DK0912558T3 (is)
DZ (1) DZ2254A1 (is)
EA (1) EA002274B1 (is)
ES (1) ES2201299T3 (is)
GT (1) GT199700075A (is)
HN (1) HN1997000079A (is)
HR (1) HRP970350B1 (is)
HU (1) HUP9903009A3 (is)
ID (1) ID18579A (is)
IL (1) IL127036A (is)
IS (1) IS4910A (is)
MA (1) MA24225A1 (is)
MY (1) MY116915A (is)
NO (1) NO986103L (is)
NZ (1) NZ332752A (is)
OA (1) OA10934A (is)
PA (1) PA8432301A1 (is)
PL (1) PL330974A1 (is)
PT (1) PT912558E (is)
SI (1) SI0912558T1 (is)
SK (1) SK176598A3 (is)
TN (1) TNSN97108A1 (is)
TR (1) TR199802685T2 (is)
TW (1) TW434237B (is)
WO (1) WO1997049702A1 (is)
YU (1) YU60198A (is)
ZA (1) ZA975581B (is)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
US6262040B1 (en) * 1996-09-04 2001-07-17 Pfizer Inc Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
WO1999023076A1 (en) * 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
HUP0004150A3 (en) * 1997-11-04 2001-08-28 Pfizer Prod Inc Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
PT1463493E (pt) 2001-12-14 2008-01-04 Serono Lab Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
RU2354648C2 (ru) 2002-07-19 2009-05-10 Мемори Фармасьютиклз Корпорейшн Соединения 6-амино-1н-индазола и 4-аминобензофурана в качестве ингибиторов фосфодиэстеразы 4
EP1539697A1 (en) 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
AU2003295656B2 (en) 2002-11-19 2010-11-11 Memory Pharmaceuticals Corporation Pyridine N-oxide compounds as phosphodiesterase 4 inhibitors
AU2004232973A1 (en) * 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
CA2584317A1 (en) * 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1928866A1 (en) * 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
DK2124944T3 (da) 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PH12012500778A1 (en) * 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (is) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
PL319758A1 (en) * 1994-10-20 1997-08-18 Pfizer Bicyclic tetrahydropyrasole pyridines and their application as medicines

Also Published As

Publication number Publication date
EA002274B1 (ru) 2002-02-28
HRP970350A2 (en) 1998-06-30
KR20000022516A (ko) 2000-04-25
AU2785797A (en) 1998-01-14
EA199801047A1 (ru) 1999-06-24
OA10934A (en) 2002-02-18
DK0912558T3 (da) 2003-08-18
CA2258285C (en) 2002-11-26
DZ2254A1 (fr) 2002-12-18
US6040329A (en) 2000-03-21
PT912558E (pt) 2003-11-28
MA24225A1 (fr) 1997-12-31
CN1223651A (zh) 1999-07-21
SK176598A3 (en) 2000-06-12
CZ423398A3 (cs) 1999-12-15
IL127036A0 (en) 1999-09-22
HUP9903009A2 (hu) 2000-05-28
AR007456A1 (es) 1999-10-27
PL330974A1 (en) 1999-06-21
ES2201299T3 (es) 2004-03-16
BR9712782A (pt) 1999-12-07
JP3152940B2 (ja) 2001-04-03
ATE244713T1 (de) 2003-07-15
TW434237B (en) 2001-05-16
MY116915A (en) 2004-04-30
AU716376B2 (en) 2000-02-24
HK1018700A1 (en) 1999-12-30
IL127036A (en) 2001-06-14
HRP970350B1 (en) 2003-04-30
BG103056A (en) 1999-10-29
EP0912558B1 (en) 2003-07-09
DE69723447T2 (de) 2003-12-24
NO986103L (no) 1998-12-23
CO4900056A1 (es) 2000-03-27
PA8432301A1 (es) 1999-12-27
TNSN97108A1 (fr) 2005-03-15
BG64052B1 (bg) 2003-11-28
AP1025A (en) 2001-11-19
IS4910A (is) 1998-11-27
HN1997000079A (es) 1997-12-26
WO1997049702A1 (en) 1997-12-31
GT199700075A (es) 1998-12-04
HUP9903009A3 (en) 2002-01-28
DE69723447D1 (de) 2003-08-14
YU60198A (sh) 1999-09-27
JPH11514668A (ja) 1999-12-14
AP9701020A0 (en) 1997-07-31
EP0912558A1 (en) 1999-05-06
ZA975581B (en) 1998-12-24
CA2258285A1 (en) 1997-12-31
NZ332752A (en) 2001-04-27
CN1080260C (zh) 2002-03-06
SI0912558T1 (en) 2003-10-31
ID18579A (id) 1998-04-23
TR199802685T2 (xx) 1999-03-22

Similar Documents

Publication Publication Date Title
NO986103D0 (no) Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE
DK1475377T3 (da) Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4
DK0740668T3 (da) Tetracykliske derivater, fremgangsmåde til deres fremstilling og deres anvendelse
NO985977D0 (no) Spiro-piperidinderivater og deres anvendelse som terapeutiske midler
NO991048D0 (no) Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)
NO20001102D0 (no) 2,3-diaryl-pyrazolo[1,5-B]pyridazinderivater, deres fremstilling og anvendelse som syklo-oksygenase 2 (COX-2) inhibitorer
DK0811007T3 (da) Pyrazol-4-yl-benzoylderivater og deres anvendelse som herbicider
DK1000039T3 (da) Substituerede quinazolinderivater og anvendelse deraf som tyrosinkinaseinhibitorer
NO980720D0 (no) Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
NO20006029D0 (no) Pyrazolinderivater, deres fremstilling og anvendelse som legemidler
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
DK1204649T3 (da) Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler
NO985095D0 (no) Substituerte indazolderivater og deres anvendelse som inhibitorer fosfodiesterase (PDE) type IV og produksjon av tumornekrosefaktor (TNF)
DK0958292T3 (da) 4-3(3-heterocyclyl-1-benzoyl)pyrazoler og deres anvendelse som herbicider
NO20003067D0 (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
NO975977D0 (no) Substituerte purinderivater, fremgangsmåter for fremstilling og anvendelse derav
DK1015444T3 (da) Pyrimidinderivater og fremgangsmåder til fremstilling deraf
NO984761D0 (no) Aminoisokinoliner og aminotienopyridinderivater og deres anvendelse som antiinflammatoriske midler
NO991560D0 (no) PDE IV som inhiberer 2-cyanoiminoimidazol-derivater
NO990246D0 (no) Akryloylsubstituert distamycinderivater, fremgangsmÕte til fremstilling av disse, og deres anvendelse som antitumor- og antivirusmidler
NO995513L (no) N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-
NO985307L (no) Distamycinderivater, fremgangsmÕte for deres fremstilling, og deres anvende
NO20001934D0 (no) 3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse
NO940130D0 (no) Benzimidazolderivater, fremgangsmaate for deres fremstilling og te rapeutisk anvendelse derav
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application